LexBlog IP

MARCH 6, 2024

announced it has signed a settlement agreement with Bayer Inc. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. On March 4, Biocon Biologics Ltd. and Regeneron Pharmaceuticals, Inc.

Marketing 52

Marketing Marketing Settlement Litigation 52

JD Supra Law

AUGUST 3, 2023

Welcome to our quarterly update relating to biologics and biosimilars, including post-grant and patent litigation challenges to blockbuster biologics. Notably, since our last update, Janssen and Amgen reached a settlement allowing for the launch of Amgen’s biosimilar to Stelara no later than January 1, 2025.

Settlement 52

Settlement Litigation Patent 52

SpicyIP

MARCH 15, 2024

Background The Petitioner, InterDigital (“ID”), initiated patent infringement proceedings against Oppo, One Plus and Redme (“defendants”) concerning 8 standard essential patents. These patents concern wireless communication technology standards (IN 262910, 295912, 313036, 319673, 320182) and H.265

Patent Infringement 59

Patent Infringement Settlement Patent Licensing 59

The IPKat

FEBRUARY 29, 2024

This New York action has been stayed pending resolution of the English litigation. This is an interesting legal question as the Copyright, Designs and Patents Act 1988 (the CDPA) brought in new performers’ rights, even for earlier performances such as Mitchell’s and Redding’s subject to transitional provisions regarding prior contracts.

Copyright 108

Copyright Reporting Contracts Settlement 108

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. Subsidies offered for Patent and Trademark (in selected categories) registration, encouraging innovation and protecting intellectual property.

Settlement 52

Settlement Intellectual Property Registration Designs 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

Yet 2020 saw a slowdown in biosimilar activity with the lowest number of annual biosimilar approvals since 2016 and fewer product launches than 2019—as well as a decrease in district court litigation and post-grant proceedings. BPCIA Litigation. Antitrust Litigation. No earlier than July 31, 2023 per settlement.

Litigation 52

Litigation Settlement Marketing Marketing 52

Patently-O

MAY 15, 2024

This wave of RFCs includes significant proposals aimed at adjusting patent fees for fiscal year 2025, refining terminal disclaimer practices, and addressing the impact of artificial intelligence on prior art and patentability. See, Dennis Crouch, USPTO Fees: Targeted Higher Fees to Push for Compact , Patently-O (Apr.

Art 44

Art Intellectual Property Designs Design 44